Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Suzanne Eleanor Dahlberg, Ph.D.

Co-Author

This page shows the publications co-authored by Suzanne Dahlberg and Lynette Sholl.
Connection Strength

0.707
  1. MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression. J Clin Oncol. 2016 Mar 01; 34(7):721-30.
    View in: PubMed
    Score: 0.166
  2. Identification of a RAS-activating TMEM87A-RASGRF1 Fusion in an Exceptional Responder to Sunitinib with Non-Small Cell Lung Cancer. Clin Cancer Res. 2020 08 01; 26(15):4072-4079.
    View in: PubMed
    Score: 0.056
  3. Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2019; 3.
    View in: PubMed
    Score: 0.054
  4. Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression. Ann Oncol. 2019 10 01; 30(10):1653-1659.
    View in: PubMed
    Score: 0.054
  5. Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications. J Clin Oncol. 2019 08 01; 37(22):1927-1934.
    View in: PubMed
    Score: 0.053
  6. Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis. Lung Cancer. 2019 07; 133:96-102.
    View in: PubMed
    Score: 0.052
  7. Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer. J Immunother Cancer. 2019 03 28; 7(1):87.
    View in: PubMed
    Score: 0.052
  8. Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib. JAMA Oncol. 2018 11 01; 4(11):1527-1534.
    View in: PubMed
    Score: 0.050
  9. Cytologic-histologic correlation of programmed death-ligand 1 immunohistochemistry in lung carcinomas. Cancer Cytopathol. 2018 04; 126(4):253-263.
    View in: PubMed
    Score: 0.048
  10. Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer. Clin Cancer Res. 2016 07 01; 22(13):3148-56.
    View in: PubMed
    Score: 0.042
  11. Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer. J Thorac Oncol. 2015 Dec; 10(12):1726-35.
    View in: PubMed
    Score: 0.041
  12. Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma. Clin Cancer Res. 2015 Jun 15; 21(12):2851-60.
    View in: PubMed
    Score: 0.039
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.